ModifiedUnitedHealthcarePolicy CSOOZNE.U

Bariatric Surgery (for Nebraska Only)

UnitedHealthcare policy governing medical necessity, eligible procedures, and coding for bariatric surgery services that apply only to members and providers in Nebraska.

Policy Summary

PayerUnitedHealthcare

PolicyBariatric Surgery (for Nebraska Only)

Policy CodePolicy CSOOZNE.U

Change TypeMaterial revision — coverage rationale clarifiedcoding list updated

Effective DateAug 1, 2025

Next Review Date

Key ActionObtain prior authorization and document multidisciplinary assessment, prior conservative therapy attempts, and indication-specific clinical documentation for bariatric and device-based procedures performed in Nebraska.

SourceLink

POLICY UPDATE CHANGES

Revisional Bariatric Surgery language was replaced to state 'Revisional Bariatric Surgery is proven and medically necessary when due to a technical failure or major complication from the initial procedure'.

Removed earlier detailed list of procedures and age-specific coverage criteria (including adjustable gastric banding, sleeve gastrectomy, vertical banded gastroplasty and specific BMI thresholds and comorbidity lists).

Applicable CPT codes 43999 and 64999 were added to the policy.

Related policy link updated for 'Minimally Invasive Procedures for Gastric and Esophageal Diseases (for Nebraska Only)'.

Nebraska-onlygeographic applicability

Yeshas material change

6 monthsIGB max duration

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

12 monthsTPS/IGB typical max

Coverage Criteria and Policy Stance

Medical necessity and procedural criteria

Covered when ALL of the following are met (state-specific requirements and listed clinical criteria):

State applicability: Patient and service must be in Nebraska and meet Nebraska DHHS Code 471 Chapter 18 requirements, including performance at a Bariatric Surgery Center of Excellence.

Conservative management: Documentation of failure of first-line treatments (dietary therapy, physical activity, behavior modification, medication) and nonpharmacological management as applicable.

Planned two-stage procedures: Initial BMI ≥ 50 kg/m2 prior to first-stage procedure; planned second-stage must occur within 2 years and individual must meet medical necessity criteria at time of second-stage procedure.Initial BMI ≥ 50 kg/m2; second stage ≤ 2 years

Revisional surgery indications: Revisional bariatric surgery is medically necessary when due to a technical failure or major complication from the initial procedure (examples include adjustable gastric band migration/slippage uncorrectable by manipulation, band erosion with bowel perforation, leak, staple-line failure, obstruction confirmed by imaging, mechanical band failure).

Uncontrollable reflux after sleeve gastrectomy: Uncontrollable reflux related to sleeve gastrectomy is covered only after failure of maximal pharmacologic therapy (for example, at least one month of double‑dose PPI and/or H2 blocker and/or sucralfate) and endoscopic confirmation of severe esophagitis (LA grade C or D) despite maximal medical management.Severe esophagitis grade C or D; ≥1 month maximal pharmacologic therapy

Revisional and device therapy considerations

Guidance and evidence summaries related to revisional surgery and device therapies

Revisional surgery consideration: Indications for revisional bariatric surgery vary by index procedure and complication; prior to revisional surgery individuals should undergo a thorough multidisciplinary assessment to distinguish anatomic causes from behavioral factors and to weigh individualized risks and benefits.

Device therapy consideration: Endoscopic and implantable devices (for example intragastric balloons, TPS, ESG, gastric neurostimulation, vagal blocking, aspiration therapy) are adjuncts to diet and behavior modification; regulatory status and recommended device durations (e.g., IGB ≈ 6 months, TPS up to 12 months) and enrollment in multidisciplinary follow-up should guide use.

Outcomes evidence for revision: Systematic reviews and cohort studies report variable outcomes after revision: some revisional operations demonstrate diabetes improvement and meaningful weight loss in selected series, but evidence is heterogeneous and revisional procedures carry higher complication rates than primary operations.

Coverage summaries by intervention

Coverage stance is inferred from evidence statements in the document:

Revisional Bariatric Surgery: Observational evidence indicates revisional bariatric surgery can yield substantial weight loss and metabolic benefit in selected patients, but is associated with higher complication rates than primary procedures; coverage decisions should consider prior procedure, specific indication, and elevated perioperative risk.

Bariatric Artery Embolization: Insufficient evidence of safety and efficacy; considered investigational pending larger randomized trials and longer follow-up.

Gastric Electrical Stimulation: Evidence preliminary and inconsistent; generally investigational until larger, long-term randomized data are available.

Intragastric Balloons: IGBs produce short-term clinically significant weight loss when combined with lifestyle therapy but long-term maintenance and safety are uncertain; considered a temporary adjunct rather than definitive therapy.

Coverage considerations for novel bariatric devices/procedures

Coverage contingent on demonstration of adequate evidence of safety and efficacy and appropriate patient selection; current evidence summarized below.

General evidence requirements: Procedures and devices require robust randomized controlled trials with long-term follow-up and acceptable safety profiles to be supported for routine coverage; many novel technologies lack this evidence base.

Technologies with concerning safety signals: Duodenal‑jejunal bypass liners (DJBL/EndoBarrier) have been associated with high rates of adverse events including hepatic abscess and gastrointestinal hemorrhage; such safety signals limit routine coverage and require demonstrable risk mitigation and monitoring plans.

Comparative effectiveness: For procedures with comparative data (for example LGCP, ESG), demonstrate that expected weight loss and safety outcomes approximate established surgical benchmarks (eg, LSG) or justify use as an alternative pathway supported by high-quality evidence.

Surgical and metabolic intervention candidacy

Coverage considerations for metabolic/bariatric surgery and related endoscopic interventions should follow guideline-based BMI and comorbidity thresholds and require multidisciplinary care.

General selection: Patient selection should follow professional society guidance: consider MBS for BMI ≥40 kg/m2 or BMI ≥35 kg/m2 with at least one significant obesity‑related comorbidity; consider bariatric/metabolic surgery at lower BMI thresholds (eg, BMI 30–34.9 kg/m2) for patients with inadequately controlled type 2 diabetes per guideline statements. Multidisciplinary evaluation and prior appropriate non‑surgical interventions are required.See society thresholds

Endoscopic device coverage criteria

Endoscopic bariatric therapies (EBTs) coverage considerations

Intragastric balloon (IGB): IGBs are FDA‑cleared as temporary adjuncts to supervised diet and behavior programs (maximum placement ~6 months); coverage should require enrollment in multidisciplinary weight management and a plan for follow‑up and post‑removal maintenance interventions.Maximum ~6 months in situ

Duodenal‑jejunal bypass sleeve (DJBL): Although DJBLs can produce weight loss and metabolic improvements in some studies, high adverse event rates (including hepatic abscess and GI hemorrhage) and device explantation limits routine coverage; use should be limited to research or special arrangements with rigorous monitoring.Caution for use beyond 12 months

Primary bariatric procedures (society position summary)

Coverage guidance and specialty society positions summarized (not a stepwise list of insurer-specific prior authorization criteria).

Adult primary bariatric surgery indications (society summaries): SG and RYGB provide durable weight loss and comorbidity improvements and are generally appropriate for patients meeting guideline BMI and comorbidity thresholds (eg, BMI ≥40 kg/m2 or BMI ≥35 kg/m2 with significant comorbidity); individual assessment is required for borderline cases and consideration should be given to GERD risk with SG.Society BMI thresholds

Endoscopic device-based therapies

Endoscopic and novel device therapies

Intragastric balloon therapy: IGB therapy is an FDA‑approved temporary endoscopic tool with randomized evidence demonstrating greater weight loss than diet alone; coverage should require multidisciplinary support, informed consent regarding device risks, and timely removal per labeled duration.Max 6 months

Revisional bariatric surgery

Revisional and reoperative surgery

Indications for reoperative bariatric surgery: Consider corrective or conversion operations for insufficient weight loss, persistent comorbid disease, or complications following the index procedure after multidisciplinary evaluation; recognize that reoperations carry higher risk and require careful patient selection and documentation of prior procedures and indications.

Adolescent metabolic and bariatric surgery

Pediatric and adolescent bariatric surgery

Adolescent eligibility and program requirements: Adolescents may be considered for metabolic and bariatric surgery using pediatric BMI percentiles or BMI cutoffs (eg, ≥120% of 95th percentile with comorbidity or ≥140% of 95th percentile), with multidisciplinary team evaluation, psychological assessment, program infrastructure for long‑term follow‑up, and a transition plan to adult care; pregnancy, unresolved substance abuse, or untreated psychiatric illness are contraindications.Pediatric BMI thresholds per society guidance

Research-only / special arrangements

Procedures/devices may be considered under the following evidence-based contexts

Research-only / special arrangements: NICE and other authoritative bodies recommend that procedures such as duodenal‑jejunal bypass liners, swallowable gastric balloons, and some novel bypass or single‑anastomosis procedures be used only in the context of research or with special arrangements due to limited quality/quantity of evidence; coverage outside research is not routinely supported without stronger evidence and governance.

FDA-labeled device criteria

Devices with FDA approval have labeled indications and adjunct requirements

FDA-labeled device indications: ORBERA intragastric balloon: adjunct for adults with BMI ≥30 and <40 kg/m2 as part of a supervised diet and behavior program, maximum placement ~6 months; Lap‑Band: indicated for adults with BMI ≥40 kg/m2 or ≥35 kg/m2 with comorbidity and prior failure of conservative measures; TransPyloric Shuttle: indicated for BMI 35.0–40.0 kg/m2 or 30.0–34.9 kg/m2 with comorbidity, to be used with diet and behavior modification.BMI thresholds as labeled

Endoscopic device-based therapies

Endoscopic and novel device therapies

General statement on device-based therapies: Endoscopic and device-based bariatric therapies (including ESG, TPS, aspiration therapy, DJBL, and others) require demonstrated safety and efficacy through high‑quality evidence and appropriate patient selection; many remain investigational or limited to specific, supervised contexts.

The policy identifies a set of procedures and device-based interventions that are considered unproven and not medically necessary for routine treatment of obesity. Examples include use of bariatric surgery solely as treatment for non‑obesity conditions, revisional bariatric surgery for indications outside those specifically described in the coverage rationale, bariatric artery embolization (BAE), gastrointestinal liners, implantable gastric electrical stimulators, intragastric balloons (for routine long‑term benefit), mini‑gastric/one‑anastomosis bypass procedures, laparoscopic greater curvature plication (LGCP), single‑anastomosis duodenal switch/SIPS, transoral endoscopic procedures (including TPS and endoscopic sleeve gastroplasty), stomach aspiration therapy, and vagus nerve blocking.

Gastrointestinal liners such as the EndoBarrier are not FDA‑approved for routine use in the United States and are limited by federal law to investigational use only; NICE guidance also recommends use of the duodenal‑jejunal bypass liner only in the context of research or with special arrangements due to limited quality and quantity of evidence.

The policy explicitly lists procedures characterized as investigational or having insufficient evidence for routine coverage, including bariatric artery embolization (BAE), various gastric electrical stimulation systems, intragastric balloons (with concerns about long‑term maintenance of benefit), stomach aspiration therapies (e.g., AspireAssist), transoral endoscopic procedures (including TPS and endoscopic sleeve gastroplasty), and other novel endolumenal or implantable devices.

Certain procedures are identified as having evidence that suggests inferiority to established surgeries or an unacceptably high rate of serious adverse events. Notably, laparoscopic greater curvature plication (LGCP) has been shown in pooled analyses and RCTs to produce less weight loss and more adverse events compared with laparoscopic sleeve gastrectomy (LSG), raising concerns about its comparative effectiveness and safety.

Data from multiple DJBL (EndoBarrier) series and trials demonstrate a high frequency of adverse events — including hepatic abscess, gastrointestinal hemorrhage, device obstructions, and pancreatitis — and substantial rates of early explantation. Because of these safety signals, prolonged use of prototype duodenal‑jejunal bypass liners beyond the durations studied is cautioned against.

The policy excludes certain patient populations from bariatric surgery: do not perform bariatric surgery in preadolescent children, in pregnant or breastfeeding adolescents (or those planning pregnancy within 2 years), or in patients with unresolved substance abuse, active untreated psychiatric disorders, or other specified relative contraindications (e.g., severe heart failure, unstable coronary disease, end‑stage lung disease, cirrhosis with portal hypertension).

Devices or procedures that do not carry a current European CE mark (for example, EndoBarrier per the cited NICE update) are restricted to use within clinical investigations; non‑CE‑marked devices may only be used under research governance and ethical approval.

The revision removed a previously detailed enumerated list of excluded procedures and prior age‑ and BMI‑based coverage language. Readers should note that several prior explicit lists and prescriptive eligibility thresholds were intentionally deleted in this policy update.

Specific endoscopic and novel bariatric interventions are singled out as unproven or not medically necessary for routine care because of limited or inconsistent evidence. These include transoral endoscopic procedures (TPS, ROSE), endoscopic sleeve gastroplasty (ESG), various intragastric balloon systems, and other emerging endolumenal devices; coverage is limited to contexts with adequate supporting evidence or research oversight.

The evidence base for revisional procedures after sleeve gastrectomy is heterogeneous and at significant risk of bias; systematic reviews report variable outcomes and insufficient high‑quality comparative data, making it difficult to define best‑practice revisional approaches in many scenarios.

Because current studies of many emerging interventions are small, nonrandomized, or single‑center with short follow‑up, the policy classifies several of these interventions as investigational or experimental. Routine coverage is not supported until robust RCT evidence with long‑term safety and effectiveness data are available.

LGCP is described in the evidence summary as inferior to laparoscopic sleeve gastrectomy in both weight‑loss efficacy and safety in pooled analyses and randomized trials; therefore LGCP may be considered not medically necessary compared with established surgical options when those alternatives are appropriate.

Prolonged implantation of the duodenal‑jejunal bypass liner (DJBL) beyond durations supported by safety data — particularly implantation longer than approximately 12 months — is not supported because of the observed high rates of adverse events and early explantation reported in multiple cohorts.

Procedures with limited or poor‑quality evidence (for example, DJBL/EndoBarrier and several novel endolumenal approaches) are recommended for use only within research settings or under special arrangements that include clinical governance, audit, and informed consent consistent with NICE recommendations.

Procedures for which efficacy evidence is inadequate (for example, swallowable gastric balloons as noted by NICE prior to research) should be confined to formal research programs; routine clinical coverage is not justified outside of such trials.

Prior policy language that explicitly defined which procedures were proven and medically necessary with specific age‑ and BMI‑based thresholds has been removed in this revision; the current policy does not restate those prior prescriptive criteria.

Applicable Procedure and Regulatory Codes

No explicit codes in this sectionmixed

No codes listed

Document does not list specific billing or procedure codes in this sectionmixed

No codes listed

Device- and procedure-related guidance (no explicit codes listed)mixed

No codes listed

Applicable Codes (added)CPT

43999	Unlisted procedure, stomach
64999	Unlisted procedure, nervous system
43999	Unlisted procedure, stomach
64999	Unlisted procedure, nervous system

BMI thresholds referenced in policy (examples and context)

Initial stage two‑stage procedureInitial BMI ≥ 50 kg/m2 prior to first‑stage bariatric procedure; second stage must occur within 2 years and patient must meet medical necessity at time of second stage.

Adult BMI classification examplesBMI 30–34.9 kg/m2 (Obesity Class I); BMI 35–39.9 kg/m2 (Obesity Class II); BMI ≥40 kg/m2 (Obesity Class III).

Adolescent severe obesity definitionsASMBS: Class II obesity = 120% of 95th percentile or absolute BMI 35–39.9 kg/m2; Class III = 140% of 95th percentile or absolute BMI ≥40 kg/m2.

BMI eligibility (TPS device)

Authorization, Documentation, and Operational Requirements

Prior Authorization

Prior Authorization and Coding Clarification

Prior authorization is required for many device-based and novel endoscopic bariatric procedures; contact UnitedHealthcare for plan-specific authorization processes. Use CPT code 43775 for laparoscopic sleeve gastrectomy (LSG) instead of unlisted 43659 when applicable.

Examples of procedures that commonly require prior authorization: LGCP, ESG, TPS (Transpyloric Shuttle), aspiration therapy (AspireAssist), vagal nerve blocking, gastric electrical stimulation, intragastric balloons, and gastrointestinal liners (EndoBarrier).
Added unlisted CPT codes 43999 and 64999 may appear in authorization workflows for unspecified procedures; include operative notes and device details when used.

Prior Authorization

Prior Authorization for Revisional and Investigational Procedures

Prior authorization is strongly recommended for revisional bariatric procedures and investigational procedures because of increased complexity, higher complication rates, and variable evidence of benefit. Revisional cases should be evaluated on an individualized basis and documented thoroughly.

Revisional indications require documentation of technical failure or major complication of the index procedure (e.g., band slippage unresponsive to adjustment, erosion, leak, staple-line failure, obstruction, mechanical band failure).

Clinical and Evidence Background

Obesity is defined using body mass index (BMI), calculated as weight in kilograms divided by height in meters squared. Obesity is associated with multiple comorbidities — including hypertension, type 2 diabetes, dyslipidemia, cardiovascular disease, osteoarthritis, and obstructive sleep apnea — and bariatric procedures aim to produce significant and durable weight loss and improvement in these obesity‑related conditions.

Body mass index (BMI) is the person’s weight in kilograms divided by the square of height in meters; BMI categories (adult ranges) include normal weight (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), and obesity classes (e.g., Class I 30–34.9 kg/m2, Class II 35–39.9 kg/m2, Class III ≥40 kg/m2). Pediatric/adolescent thresholds are assessed using percentiles (e.g., Class II = ≥120% of the 95th percentile).

Key Terms and Device Definitions

Revisional Bariatric Surgery definitions (conversion, corrective, reversal)

Conversion (revisional) definitionConversion: a second bariatric procedure that changes the bariatric approach from one procedure to a different type of procedure.

Corrective (revisional) definitionCorrective: a procedure that corrects or modifies anatomy of a previous bariatric procedure to achieve the original desired outcome or correct a complication.

Reversal (revisional) definitionReversal: a procedure that restores the original anatomy.

Los Angeles (LA) Classification of Oesophagitis (Grades A–D)

LA classification Grade AOne (or more) mucosal break no longer than 5 mm that does not extend between the tops of two mucosal folds.

LA classification Grade B

Policy Updates and Material Changes

2025-10-01related_policy_update

Related policy reference link updated to reflect the current title for 'Minimally Invasive Procedures for Gastric and Esophageal Diseases (for Nebraska Only)'.

2025-08-01coverage_rationale_revisionLatest

Replaced prior revisional bariatric surgery wording with: 'Revisional Bariatric Surgery is proven and medically necessary when due to a technical failure or major complication from the initial procedure.'

2025-08-01

Policy Summary

PayerUnitedHealthcare

PolicyBariatric Surgery (for Nebraska Only)

Policy CodePolicy CSOOZNE.U

Change TypeMaterial revision — coverage rationale clarifiedcoding list updated

Effective DateAug 1, 2025

Next Review Date

SourceLink

On This Page

Laparoscopic Greater Curvature Plication (LGCP): Evidence demonstrates inferior weight-loss durability and potentially higher adverse events versus sleeve gastrectomy; use is unsupported as equivalent to established surgical options without stronger comparative data.

Stomach Aspiration Therapy: Current data are limited and of low-to-moderate quality; aspiration therapy remains investigational for routine coverage pending larger randomized trials and longer-term outcomes.

TPS labeled BMI eligibility

TransPyloric Shuttle PMA indication: adults with BMI 35.0–40.0 kg/m2, or BMI 30.0–34.9 kg/m2 with one or more obesity‑related comorbid conditions.

Use contextTPS intended to be used in conjunction with a diet and behavior modification program; FDA PMA granted April 2019.

Device regulatory noteConfirm FDA approval status and patient meets labeled BMI/comorbidity criteria before authorization.

IGB duration — Approximately 6 months

Standard IGB in‑situ durationApproximately 6 months (manufacturer guidance and FDA/ASMBS labeling reference maximum placement period of 6 months).

Clinical contextIGBs are intended as adjuncts to diet, exercise, and behavioral counseling; timely removal optimizes safety.

Evidence noteRandomized trials demonstrate short‑term weight loss during balloon treatment, with uncertainty about long‑term maintenance after removal.

TPS therapy duration — Up to 12 months

TPS maximum therapy durationTransPyloric Shuttle approved for up to 12 months of therapy per FDA PMA labeling.

Adjunct requirementIntended to be used with diet and behavior modification program during therapy duration.

Authorization implicationConfirm multidisciplinary follow‑up availability for duration of TPS use when authorizing therapy.

BMI ranges referenced across studies/trials

Trials including BMI 30–50 kg/m2DJBL trials included participants with BMI ranges up to 30–50 kg/m2 in various studies (e.g., RCTs and cohorts).

Orbera/IGB trial BMI rangesPivotal and RCT studies of intragastric balloons enrolled adults with BMI commonly in the 30–40 kg/m2 range (e.g., REDUCE trial mean BMI ~35.4 kg/m2).

LGCP trial BMI limitsLGCP randomized trials excluded extreme BMI values (example exclusion: BMI >65 kg/m2) and enrolled typical morbid obesity ranges (reported cohorts 35–65 kg/m2 limits).

BMI thresholds for metabolic/bariatric interventions (guideline examples)

Common guideline surgical thresholdsProfessional guidelines commonly recommend bariatric/metabolic surgery for BMI ≥40 kg/m2, or BMI ≥35 kg/m2 with at least one severe obesity‑related comorbidity.

Lower BMI consideration for T2DGuidelines (ADA/AACE/ASMBS) consider BMI 30–34.9 kg/m2 as potential indication for metabolic surgery in patients with inadequately controlled T2D despite optimal therapy.

Ethnicity adjustmentGuidelines advise downward BMI threshold adjustments for Asian ancestry (e.g., reduce thresholds by ~2.5 kg/m2 per ADA/NICE guidance).

BMI thresholds (various society recommendations) — examples for SG/RYGB and NICE

SG/RYGB typical indicationsSociety summaries note SG and RYGB indications commonly BMI ≥40 kg/m2 or BMI ≥35 kg/m2 with comorbidities; SG is widely used but may worsen GERD—preoperative counseling advised.

NICE expedited surgery guidanceNICE recommends expedited surgical referral for BMI ≥35 kg/m2 with recent‑onset T2D or consideration at lower BMI (30–34.9) if recent‑onset T2D and specialist assessment is available.

Pediatric/adolescent thresholdsAAP/Endocrine Society use percentile‑based cutoffs (e.g., Class II = ≥120% of 95th percentile or BMI ≥35; Class III = ≥140% of 95th percentile or BMI ≥40) with programmatic requirements.

Device‑specific BMI labeling (ORBERA, Lap‑Band, TransPyloric Shuttle)

ORBERA labeled BMI indicationORBERA Intragastric Balloon System indicated as adjunct for adults with BMI ≥30 and <40 kg/m2; maximum placement period 6 months.

Lap‑Band labeled BMI indicationLap‑Band (Adjustable Gastric Band) indicated for adults with BMI ≥40 kg/m2, or BMI ≥35 kg/m2 with one or more severe comorbid conditions; prior failure of conservative measures required.

TransPyloric Shuttle labelingTransPyloric Shuttle PMA indicates use for adults with BMI 35.0–40.0 kg/m2 or BMI 30.0–34.9 kg/m2 with one or more obesity‑related comorbid conditions; intended with diet and behavior modification.

Demonstrate attempts at non-surgical corrective measures (e.g., band manipulation/adjustment) prior to authorizing revision.

Prior Authorization

Device-Specific Authorization Considerations

Authorization is required for FDA-approved implantable devices and novel endoscopic bariatric procedures; documentation must include indication, prior conservative therapy, device regulatory status, and a multidisciplinary care plan. Devices with investigational status (e.g., EndoBarrier) require enrollment in a research protocol or special arrangements.

IGB (e.g., ORBERA) — maximum in-situ time is 6 months per FDA labeling; prior conservative weight-loss strategy must be documented.
TPS (Transpyloric Shuttle) — FDA PMA-approved and indicated for up to 12 months; include BMI and comorbidity criteria and evidence of enrollment in diet/behavior program.
Gastrointestinal liners (EndoBarrier/DJBL) — not FDA-approved for general use in U.S.; limited to investigational use and typically require research oversight and special governance.

Prior Authorization

Authorization Limits and Follow-up for Intragastric Balloons and Investigational Devices

Intragastric balloon therapies and other investigational devices have defined authorization limits and monitoring requirements. For balloons, document multidisciplinary program participation and plan for timely removal and follow-up. For investigational liners and novel devices, note duration limits and heightened safety monitoring.

IGB: document failure of conservative therapies, enrollment in supervised diet/behavior program, and plan for removal within 6 months.
IGB follow-up: routine clinical, nutritional, and device checks to mitigate risks (deflation, migration, obstruction).
DJBL/EndoBarrier: document investigational status, limited approved duration in trials (typically ~12 months), and risks including hepatic abscess, GI hemorrhage, obstruction — prolonged use beyond studied durations may be denied.

Prior Authorization

Revisional Surgery Pre-Assessment and Authorization

Revisional surgery requires pre-assessment and multidisciplinary evaluation. Prior authorization may be required given higher complication rates and variable outcomes; failure to meet documentation requirements can lead to denial.

Required pre-revision documentation: multidisciplinary assessment, reason for revision, prior procedure type and operative report, attempts at non-surgical correction, current BMI and comorbidity status, and risk/benefit discussion.
Demonstrate technical failure or major complication from the index operation (e.g., persistent leak, obstruction, irreparable band erosion) to meet revisional coverage rationale.

Documentation Required

Monitoring Requirements for Aspiration Therapy

Monitoring plans must be documented for long-term device therapies such as stomach aspiration (AspireAssist). Authorization and continued coverage may depend on evidence of regular follow-up and management of stoma site, metabolic monitoring, and device-related complications.

Document schedule for weight-loss monitoring, stoma site checks, electrolyte and metabolic surveillance, and plan for troubleshooting or tube replacement.
Failure to document regular monitoring and follow-up may result in denial due to safety concerns.

Denial Risk

Investigational Procedures and Evidence-Based Denial Risk

Many endoscopic and device-based procedures are considered investigational or have insufficient evidence; prior authorization should include evidence review and may result in denial if procedures are investigational, have safety concerns, or lack durable efficacy.

Procedures often labeled investigational: bariatric artery embolization, gastric electrical stimulation, single-anastomosis procedures with limited data, various novel endoscopic bypass devices, and some aspiration or implantable devices with limited RCT data.
LGCP has demonstrated inferior effectiveness and higher AE rates compared with LSG — expect additional authorization scrutiny or denial for LGCP.
Aspiration therapy evidence is limited and mixed; while some low-quality data show benefit, limitations may prompt requirement for research enrollment or denial.

Documentation Required

Required Clinical Documentation, Consent, and Monitoring

Documentation requirements for authorization decisions are detailed and must be complete. Provide preoperative evaluations, nutritional monitoring plans, informed consent (including contraception counseling for reproductive-age women), and adolescent program documentation where applicable.

Required clinical documentation: obesity-focused history, prior weight-loss attempts, behavioral and psychosocial assessment, laboratory and diagnostic testing, and summary of conservative management efforts.
Nutritional screening and monitoring plan: pre/postoperative micronutrient testing and follow-up schedule.
Informed consent must include discussion of procedure-specific AEs, device-specific risks, and contraception counseling for women of reproductive potential.
Adolescents: document multidisciplinary team evaluation, evidence of physiologic maturity and transition plan to adult care; MBSAQIP criteria or equivalent program accreditation should be noted.
Device labeling documentation: for FDA-approved devices (e.g., ORBERA, TPS), include device indication, documented failure of conservative strategies, and enrollment in a long-term supervised behavior/diet program.

Note

Plan-Level Governance and Research-Only Arrangements

Plan-level governance applies: this medical policy is informational and federal, state, or contractual plan terms govern coverage decisions. When procedures are recommended by external bodies (e.g., NICE) only in research settings, UnitedHealthcare may require research enrollment or special arrangements for coverage.

If state-specific rules apply (e.g., Nebraska requirement for Bariatric Surgery Center of Excellence), include facility accreditation in authorization documentation.
In case of conflict between this policy and federal/state/contractual requirements, the latter govern coverage decisions.

One (or more) mucosal break more than 5 mm long that does not extend between the tops of two mucosal folds.

LA classification Grades C–DGrade C: mucosal break continuous between tops of two or more folds involving <75% circumference; Grade D: involves ≥75% of esophageal circumference.

Endoscopic Sleeve Gastroplasty (ESG) definition

ESG definitionEndoscopic sleeve gastroplasty (ESG): a minimally invasive endoscopic suturing procedure performed via the mouth to reduce gastric capacity by creating a tubular stomach without resection (example device: OverStitch).

Comparative contextESG reduces gastric volume endolumenally and has shown moderate total body weight loss (~14–20% in observational data) but less than surgical sleeve gastrectomy in comparative analyses.

Device exampleOverStitch endoscopic suturing system is commonly used to perform ESG (510(k) clearance K181141).

Intragastric Balloon (IGB) definition

IGB definitionIntragastric balloon (IGB): an acid‑resistant balloon inserted into the stomach and inflated with saline or air to occupy gastric volume and promote early satiety as an adjunct to diet, exercise, and behavioral counseling.

Therapy intentTemporary endoscopic device intended to produce short‑term weight loss during placement; timely removal and multidisciplinary follow‑up recommended to optimize safety and maintenance.

Typical clinical evidenceRandomized trials (e.g., REDUCE) enrolled adults with BMI 30–40 kg/m2 and demonstrated greater weight loss versus diet/exercise alone during treatment period.

Stomach aspiration therapy (AspireAssist) definition

Aspiration therapy definitionStomach aspiration therapy (e.g., AspireAssist): a surgically placed endoluminal gastrostomy tube that allows aspiration of a portion of gastric contents after meals to reduce caloric absorption, intended for long‑term use with lifestyle therapy and medical monitoring.

Monitoring needsRequires regular monitoring of weight loss progress, stoma site health, and metabolic and electrolyte balance during long‑term use.

Evidence summarySmall studies report maintained weight loss up to 4 years (e.g., ~18% TWL) with pooled SAE rates around 4.1%; higher‑quality RCTs are needed.

Bariatric artery embolization (BAE) definition

BAE definitionBariatric artery embolization (BAE): endovascular occlusion (often of the left gastric artery) intended to reduce ghrelin and induce weight loss; current evidence limited to small case series and early RCTs.

Evidence limitationsAvailable studies include small RCTs and case‑series meta‑analyses with heterogeneous techniques and follow‑up; further robust trials needed for safety and efficacy conclusions.

Reported outcomesSmall trials reported modest TBWL (e.g., mean ~7.4 kg at 6 months in one RCT ITT analysis) with limited long‑term control groups.

Gastric electrical stimulation (GES / CLGES) definition

GES/CLGES definitionGastric electrical stimulation (GES/CLGES): implantable electrical stimulation systems intended to alter gastric motility or satiety to induce weight loss; evidence is preliminary and limited to small feasibility and prospective studies.

Clinical resultsSmall studies report variable weight loss and mixed metabolic effects; larger well‑designed RCTs with long‑term follow‑up are required.

Device considerationsIncludes closed‑loop and open systems; device‑related complications and lead failures have been reported and monitored in trials.

Intragastric balloon (IGB) definition (device variants)

IGB device variantsIntragastric balloons include endoscopically placed fluid‑ or air‑filled balloons (e.g., ORBERA) and dual‑balloon systems; some are swallowable or sequentially used but all are temporary adjuncts to lifestyle programs.

Regulatory contextORBERA has FDA approval (PMA p140008) with labeled indication for BMI ≥30 and <40 kg/m2 and maximum placement 6 months; other devices have varied approvals or investigational status.

Safety considerationsBalloon use associated with early accommodative symptoms, occasional deflation/migration, and rare serious complications; follow‑up is essential to reduce risk.

Laparoscopic greater curvature plication (LGCP) definition

LGCP definitionLaparoscopic greater curvature plication (LGCP): a surgical plication of the greater curvature to reduce gastric volume without resection.

Comparative findingsRCTs and meta‑analyses indicate LGCP provides initial weight loss but is generally inferior to laparoscopic sleeve gastrectomy (LSG) in durability and associated with higher adverse events in pooled analyses.

Evidence gapLong‑term comparative effectiveness and safety data remain limited; additional robust RCTs with long‑term follow‑up are needed.

Stomach aspiration (AspireAssist) definition

AspireAssist definition (duplicate)Stomach aspiration (AspireAssist): percutaneous gastrostomy‑based aspiration of gastric contents after meals to reduce calorie absorption; intended with lifestyle therapy and continuous monitoring.

Clinical monitoringRequires regular follow‑up for stoma site health, metabolic and electrolyte balance, and weight loss progress.

Evidence summarySmall studies report maintained weight loss up to 4 years but evidence quality is low; larger RCTs are needed.

Aspiration therapy (AT) definition

Aspiration therapy (AT) general definitionAspiration therapy: percutaneously or endoscopically placed device (e.g., AspireAssist) enabling removal of gastric contents after meals to facilitate weight loss as part of comprehensive lifestyle therapy and monitoring.

Reported outcomesSystematic reviews report ~17–18.6% TWL maintained in small cohorts out to 3–4 years with pooled serious adverse event rate ~4.1%.

Authorization considerationsLong‑term device maintenance and monitoring requirements should be documented when considering coverage due to device management needs.

Endoscopic sleeve gastroplasty (ESG) definition (device examples)

ESG device examplesEndoscopic sleeve gastroplasty commonly performed using endoscopic suturing systems such as OverStitch (510(k) K181141).

Procedure descriptionESG reduces gastric capacity via endoscopic suturing delivered through the mouth, creating a tubular stomach without resection.

Effectiveness contextObservational data report moderate TBWL (~14–20%), but comparative analyses show less weight loss and mixed safety signals versus surgical sleeve gastrectomy.

Duodenal‑jejunal bypass liner (DJBL/EndoBarrier) definition

DJBL/EndoBarrier definitionDuodenal‑jejunal bypass liner (DJBL/EndoBarrier): an endoscopically placed impermeable sleeve that diverts chyme from the proximal small bowel to induce weight loss and metabolic effects.

Safety concernsStudies report high rates of adverse events including device obstruction, GI hemorrhage, and hepatic abscess; many patients experience AEs and weight regain after removal.

Regulatory contextDJBL is not FDA‑approved for routine use in the U.S.; investigators and regulators advise caution and consider use within clinical trials.

Duodenal‑jejunal bypass sleeve (DJBL / EndoBarrier) definition (duplicate context)

DJBL (duplicate context)The duodenal‑jejunal bypass sleeve (EndoBarrier) bypasses proximal small bowel mucosa to induce weight loss and metabolic changes but is associated with significant adverse events in some series.

Clinical outcomesReported mean %TWL and weight changes varied; high AE frequency (e.g., 74% experiencing ≥1 AE in some cohorts) and device explantation common.

Use recommendationConsidered investigational/limited to research in many jurisdictions due to safety profile and limited long‑term evidence.

Intragastric balloon (IGB) definition (FDA‑approved context)

IGB (FDA‑approved) definitionFDA‑approved intragastric balloons (e.g., ORBERA) are temporary endoscopic devices placed to promote satiety and weight loss, indicated as adjuncts for adults with BMI ≥30 and <40 kg/m2 with a supervised diet and behavior program; maximum placement ~6 months.

Regulatory noteORBERA PMA p140008 referenced; device labeling requires prior failure of conservative strategies and supervised program participation.

Follow‑up importanceAppropriate follow‑up is essential to reduce risks such as spontaneous deflation and bowel obstruction and to support weight‑loss maintenance.

Reoperation (reoperative bariatric surgery) definition

Reoperation definitionReoperation (reoperative bariatric surgery): an operation after the first bariatric operation; subdivided into corrective operations (address complications or incomplete treatment without changing index operation) and conversions (changing the index operation to a different type).

Indications summaryReoperations may be performed for insufficient weight loss, persistent comorbidity, or complications after index procedure; reoperations carry higher risks than primary procedures.

Coverage rationale linkagePolicy states revisional bariatric surgery is proven and medically necessary when due to technical failure or major complication from the initial procedure.

ORBERA Intragastric Balloon System definition and labeled indication

ORBERA system descriptionORBERA Intragastric Balloon System: FDA‑approved adjunct to weight reduction in adults with BMI ≥30 and <40 kg/m2, to be used with a supervised diet and behavior modification program; maximum placement period 6 months.

Regulatory referencePMA reference: p140008 (FDA).

Labeling requirementIndicated for adults who have failed conservative weight‑reduction strategies and require supervised program participation.

Lap‑Band / Adjustable Gastric Band definition and labeled indication

Lap‑Band definitionLap‑Band / Adjustable Gastric Band: an FDA‑approved adjustable gastric banding system indicated for severely obese adults (BMI ≥40 kg/m2, or BMI ≥35 kg/m2 with comorbidity) after failure of conservative treatments; contraindicated in patients <18 years.

Labeling contextApproved via PMA (BioEnteric/LAP‑BAND) and labeling requires prior failure of supervised diet, exercise, and behavior modification.

Clinical implicationDevice‑specific labeling should guide coverage decisions and documentation requirements for authorization.

TransPyloric Shuttle definition and labeled indication

TransPyloric Shuttle definitionTransPyloric Shuttle: a non‑balloon, space‑occupying endoscopic device consisting of connected silicone bulbs delivered and removed endoscopically; granted FDA PMA for weight reduction in adults with BMI 35.0–40.0 kg/m2 or BMI 30.0–34.9 kg/m2 with ≥1 obesity‑related comorbidity.

Intended useIntended for outpatient transluminal delivery/removal and to be used with diet and behavior modification program for the duration of therapy (up to 12 months).

Authorization considerationConfirm patient BMI/comorbidity eligibility and ability to participate in adjunctive lifestyle program when authorizing TPS.

Revisional Bariatric Surgery coverage rationale (definition entry)

Coverage rationale summaryRevisional Bariatric Surgery is proven and medically necessary when due to a technical failure or major complication from the initial procedure.

Examples of qualifying complicationsIncludes adjustable gastric band migration/erosion uncorrectable by manipulation, bowel perforation, leak, staple‑line failure, obstruction confirmed by imaging, and mechanical band failure.

Documentation requirementRecords must document prior attempts at nonpharmacological management and corrective maneuvers (e.g., band adjustment) where applicable to demonstrate indication for revision.

Removed prior detailed list of specific procedures and age/BMI-based coverage criteria previously enumerated in the policy (including adjustable gastric banding, sleeve gastrectomy, vertical banded gastroplasty and related thresholds).

2025-08-01codes_added

Added unspecified procedure CPT codes 43999 and 64999 to the Applicable Codes section of the policy.